Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

Press Release

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA  and ROCKVILLE, MD – January 11, 2021 – Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million…

Details

Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Press Release

– SNS-301 demonstrated prolonged partial response and improvement in immune markers in PD-L1 negative disease patient with 43% tumor reduction – 30+ week stable disease observed in 2 patients BOSTON, Mass. & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation immunotherapies for the treatment of cancer and infectious diseases, today reported…

Details

Sensei Biotherapeutics Announces Appointment of Anu Hoey as Chief Business Officer

Press Release

GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the appointment of Anu Hoey as Chief Business Officer, responsible for leading business and corporate development. “We are thrilled to welcome Anu to our team to help drive our strategic…

Details

Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers

Press Release

BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, today announced the completion of a $28.5 million equity financing. The financing was co-led by Cambrian Biopharma and H&S Ventures, along with participation from new investors Future Ventures, Christian Angermayer’s Apeiron Investment…

Details

Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301

Featured, Press Release, Recent

Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020   BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the…

Details

Sensei Biotherapeutics Announces Appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer

Press Release

GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer, responsible for leading clinical and development strategy and operations. Dr. Fjällskog joins Sensei from Merus, where she served as Vice President Clinical Development and led the development…

Details

Sensei Biotherapeutics Completes Acquisition of Alvaxa Biosciences, a Camelid Antibody Therapeutics Company

Press Release

Acquisition Advances Sensei’s Core Capabilities in Immunology and Antibody Engineering by Supercharging its ImmunoPhage™ Platform GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the acquisition of Alvaxa Biosciences, Inc., a camelid antibody therapeutics company with technology licensed from Fred Hutchinson Cancer Research Center. READ MORE

Details

Sensei Biotherapeutics Appoints Robert Pierce, M.D., as Chief Scientific Officer

Press Release

Opening of New Boston Facility Focused on Cancer Drug Development and Expansion of Expert Oncology Team GAITHERSBURG, Md. & BOSTON–(BUSINESS WIRE)–Sensei Biotherapeutics., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Robert Pierce, M.D., as chief scientific officer and the opening of its Boston office. Sensei’s facility in Boston will include…

Details

Sensei Biotherapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Press Release

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 2:50 p.m. ET in New York, NY. READ MORE

Details

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-301 in Patients with ASPH-Positive Head and Neck Cancer

Press Release

GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating SNS-301 in patients with ASPH‑positive head and neck cancer who have previously received immune checkpoint inhibitors. SNS-301 is a first-in-class immunotherapy candidate utilizing a bacteriophage viral vector…

Details